L-SELECTIN, CLEC6AAND GALECTIN-16 AS NEW BIOCHEMICAL TOOLS FOR DIAGNOSIS OF UNTREATED PATIENTS WITH PCOS

Abstract

Polycystic ovary syndrome (PCOS) is currently recognized as a complex heterogeneous disease characterized by hyperandrogenism, amenorrhea, oligomenorrhoea, an ovular infertility, and ovarian polycystic syndrome with a range of phenotypic and demographic variations. PCOS is among the most common endocrine disorders in women. Its diagnostic and phenotypic complexities present significant challenges to the clinical and basic research community. this study included samples of 90 women of reproductive age (20-45 years). They were distributed into two groups. The first: 45 patients who were diagnosed with polycystic ovary syndrome (PCOS) through the simultaneous appearance of 3-4 symptoms that are essential for diagnosis. Their ages ranged between 20-33 years old. The second group (the control group) included 45 women who were completely free of symptoms of PCOS, based on clinical examinations and ultrasound examinations. Sandwich-ELISA technique was applied to determine the level of L-Selectin, CLEC6A and Galectin-16 in the serum samples of the study individuals. The results of the present study showed a significant (p=0.000) decrease in the levels of L-Selectin in the samples of patients with PCOS comparison to healthy individuals. The study proved that there were significant differences (p=0.000) between the two study groups, as an increase in CLEC6A level was observed in the diseased group compared to the healthy group, while no significant differences (p=0.612) in the levels of galectin-16 in PCOS patients and the control group. The relation between CLEC6A and Galectin-16 was statistically (p=0.016) negative in ~76% of PCOS patients, while the study indicates that CLEC6A is associated with galectin-16 with a positive significant relationship in approximately 79% of the control group members. From the current work, it can be concluded that both L-Selectin and CLEC6A can be excellent diagnostic tools for PCOS. Moreover, evaluating the relationship between CLEC6A and galectin-16 to definitively predict the possibility of a female suffering from polycystic ovary syndrome when the result of testing the relationship between the two parameters isnegative.